In the current month, CLDI has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CLDI average Analyst price target in the last month is 10.000.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
Strong Buy
0
0
0
0
0
1
1
1
Buy
0
0
0
0
0
0
0
0
Hold
0
0
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
0
0
Sell
0
0
0
0
0
0
0
0
Total
0
0
0
0
0
1
1
1
CLDI Analyst Rating for Peer Comparison
Updated: Nov 5, 2026
Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Ratings
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ascendis Pharma A/S
ASND
9
13
1
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
Forecast
--
--
--
Actual
-6.86
-47.01
-1.47
Surprise
--
--
--
FAQs
What is the analyst rating for Calidi Biotherapeutics Inc?
Based on the ratings of Calidi Biotherapeutics Inc's stock from 0 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.